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ABSTRACT
Recent studies have shown that high ATP levels exhibit direct cytotoxic effects 
on several cancer cells types. Among the receptors engaged by ATP, P2X7R is the 
most consistently expressed by tumors. P2X7R is an ATP-gated ion channel that could 
drive the opening of a non-selective pore, triggering cell-death signal. We previously 
demonstrated that acute myeloid leukemia (AML) cells express high level of P2X7R. 
Here, we show that P2X7R activation with high dose ATP induces AML blast cells 
apoptosis. Moreover, P2X7R is also expressed on leukemic stem/progenitor cells (LSCs) 
which are sensitive to ATP-mediated cytotoxicity. Conversely, this cytotoxic effect was 
not observed on normal hematopoietic stem/progenitor cells (HSCs). Notably, the 
antileukemic activity of ATP was also observed in presence of bone marrow stromal 
cells and its addition to the culture medium enhanced cytosine arabinoside cytotoxicity 
despite stroma-induced chemoresistance. Xenotransplant experiments confirmed ATP 
antineoplastic activity in vivo. 
Overall, our results demonstrate that P2X7R stimulation by ATP induced a 
therapeutic response in AML at the LSC level while the normal stem cell  compartment 
was not affected. These results provide evidence that ATP would be promising for 
developing innovative therapy for AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a hematopoietic 
stem cell disorder characterized by clonal proliferation of 
myeloid precursors with an inhibition in differentiation, 
leading to accumulation of immature cells at various 
stages. Approximately 50% of leukemia patients survive 
their disease. The percentage of long-term survivors drops 
down to 5–15% in elderly patients. Disease relapse and 
toxicity of therapy, especially in elderly patients, represent 
today the major limiting factors in leukemia treatment. 
Despite the introduction of novel target therapies in 
the treatment of cancer, chemotherapy remains as 
primary option for AML patients. In this scenario, novel 
therapeutic approaches that aim to reduce toxicity and to 
improve the efficacy of treatment are expected to greatly 
improve long-term outcomes in leukemia patients. 
ATP is the key energy currency as well as an 
ubiquitous extracellular messenger. Depending on its dose 
and the purinergic P2 receptor (P2R) subtype engaged, 
ATP can trigger many different cell responses, including 
cell proliferation, differentiation and apoptosis [1]. 
Over the past decade, various studies described a 
direct cytotoxicity of extracellular ATP on different tumor 
cell types, such as melanoma, glioma and colon cancer 
cells [1–3]. ATP acts binding fifteen different purinergic 
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receptors but only five have been described to be involved 
in ATP direct tumor killing: P2X5R, P2X7R, P2Y1R, 
P2Y2R and P2Y11R. Among these, P2X7R is the most 
consistently expressed by tumor cells [4, 5].
P2X7R is an ATP plasma membrane ion channel 
that, upon transiently stimulation, behaves like a cation-
selective channel permeable to Na+, K+ and Ca2+. 
It shows a growth-promoting activity, which seems 
to be indispensable for different cell types, such as 
T lymphocyte or primary mouse microglia cells [6–9]. 
One of the most interesting feature of the P2X7R trophic 
effect is its ability to promote survival and growth in 
absence of serum [10, 11]. Therefore, it is not surprising 
that malignant tumors overexpress this receptor. Several 
groups have described increased expression of P2X7R 
in prostate [12], breast and skin cancers [13, 14], 
neuroblastoma [15, 16], leukemia [17, 18] and thyroid 
papillary carcinoma [19]. This observation, supported by 
recent studies [20], suggested that P2X7R could have an 
important role in carcinogenesis and tumor progression 
[21]. However, P2X7R is an unusual receptor and its 
massive, unlike tonic low-level, stimulation by ATP 
leads to the formation of a non selective and permanently 
opened pore in the cell membrane, triggering cell death 
signals. Over the past years, several reports showed the 
possibility to induce tumor inhibition or killing by P2X7R 
activation [22, 23].
We previously reported that unlike normal CD34+ 
cells [24], activation of P2R signaling by ATP inhibits 
leukemic cell functions [18]. Since it has opposite effect 
on hematopoietic stem cells (HSCs) and leukemic cells, 
ATP is a good candidate for developing therapies with 
low toxicity on HSC compartment, which is essential 
for a complete hematologic recovery after therapy. In 
the present study, we extended our previous biological 
findings by testing the therapeutic potential of high 
dose of ATP in vitro and in vivo. We demonstrated that 
leukemic stem cells (LSCs) are sensitive to ATP treatment 
being induced to apoptosis while the same treatment 
did not affect normal HSC compartment. Moreover, the 
addition of ATP enhanced the antileukemic activity of 
cytosine arabinoside and counteracted stroma-mediated 
chemoresistance. In addition, we demonstrated the in vivo 
antileukemic effect of ATP treatment. Our data, combined 
with published studies, suggest the antitumor potential 
of purinergic-based drugs and propose P2X7R as target 
for development of therapeutic strategies in leukemia 
treatment. 
RESULTS
P2X7R activation by ATP induces apoptosis of 
primary AML cells
We first investigated whether ATP, via P2X7R 
activation, induces apoptosis in primary AML cells. In line 
with previous report [23], we showed that ATP exerted 
direct cytotoxicity on AML cells reducing cell viability 
in a dose dependent manner. This effect is inhibited 
by P2X7R blockage through the addition of P2X7R 
antagonist, AZ 10606120 (Figure 1A). 
In order to assess if ATP cell death induction was 
due to apoptosis, we treated AML cells isolated from 23 
AML samples with increasing doses up to 5 mM ATP 
for 48 h in presence or absence of P2X7R antagonist. 
As shown in Figure 1B, P2X7R activation by 5 mM ATP 
significantly increased apoptotic AML cells as compared 
to control (47.5 ± 7.9% vs 26.6 ± 5.8%, p < 0.05). To 
further confirm P2X7R involvement, we treated AML 
cells that had previously undergone to P2X7R silencing 
by short interfering RNAs (siRNA) (Figure 1C). 
Accordingly, whereas mock-nucleofected cells maintained 
the capability to respond to ATP stimulation (fold increase 
of apoptotic cells 2.3 ± 0.5, p < 0.05), cells transduced 
with anti-P2X7R siRNA failed to respond (Figure 1D), 
indicating that P2X7R activation is essential for apoptosis.
To better characterize apoptotic process after 
ATP treatment, we analyzed two specific markers of 
apoptosis: caspase activity and mitochondrial membrane 
potential (ΔΨm). To confirm mitochondrial membrane 
damage after 48 h ATP treatment, we stained AML cells 
with the cationic lipophilic dye JC-1 which accumulates 
as aggregates or monomers in healthy or damaged 
mitochondria, respectively. ATP exposure resulted in ΔΨm 
reduction in treated as compared to untreated AML cells as 
demonstrated by the increase of JC1 monomer percentage 
(32.6 ± 7.5% and 19.5 ± 5.8% respectively, p < 0.05) 
matched with significant decrease of JC-1 aggregates 
(75.9 ± 5.3% in treated cells and 59.7 ± 6.1% in untreated 
cells, p < 0.01). Such process was inhibited by the addition 
of AZ 10606120 (Figure 2A–2B). 
Then we evaluated caspase cascade activation 
by analyzing the expression of caspase-3 active form. 
Immunofluorescence analysis revealed an increased 
expression of active caspase-3 in AML cells after ATP 
exposure (Figure 2C). Caspase-3 activation was also 
confirmed by flow cytometry analysis (Figure 2D–2E). 
The percentage of active caspase-3+ cells was 12.3 ± 2.0% 
in untreated cells and 27.3 ± 2.7% in ATP treated cells 
(p < 0.05), blockage of P2X7R by AZ10606120 restored 
basal level of caspase-3 activation (13.0 ± 4.4%).
Taken together our results indicate that primary 
AML cells undergo apoptosis after P2X7R stimulation 
by high ATP dose through caspase and mitochondria 
pathways activation.
Bone marrow stroma does not affect ATP 
treatment efficacy
In the last decade, emerging evidence showed that 
bone marrow (BM) microenvironment is a key regulator 
of leukemia growth and its interaction with leukemia cells 
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is one of the cause of chemoresistance [25]. In order to 
mimic ATP effects on leukemia BM microenvironment, 
we treated AML cells in presence of normal or leukemic 
mesenchymal stromal cells (MSCs). Both normal and 
AML stroma protected AML cells from spontaneous 
apoptosis, as expected, but did not affect ATP treatment 
efficacy. Compared to spontaneous apoptosis of blast 
cells, P2X7R activation with 5 mM ATP induced 1.9 ± 0.3, 
1.7 ± 0.4 and 1.5 ± 0.2 fold increase of apoptosis in 
AML cells cultured alone, with normal MSCs or AML 
MSCs, respectively (p < 0.05). Blockage of P2X7R by 
AZ10606120 restored basal level of apoptotic cells in each 
group (Figure 3A).
Since P2X7R pore formation facilitates the passage 
of hydrophilic chemotherapeutic agents [26], we expected 
to potentiate the cytotoxic effect of antineoplastic drugs 
and to bypass stroma induced-chemoresistance, by using 
ATP as adjuvant. We first examined  the synergistic effect 
of combining the cytotoxicity of cytarabine (ARA-C) 
with the pro-apoptotic activity of ATP. To this end, 
AML cells were treated for 48 h with increasing doses 
of ARA-C with or without ATP. As shown in Figure 3B, 
AML cell apoptosis was significantly higher when ATP 
and ARA-C were combined as compared  to their use as 
single compound (% of Annexin-V+ cells: 4 µM ARA-C+ 
ATP 78.7 ± 5.3% vs ATP 58.6 ± 5.3% and ARA-C 59.5 ± 
5.4%, p < 0.05). Interestingly, the addition of ATP allows 
to reach a high toxicity using lower doses of ARA-C. 
We next investigated if the observed synergistic effect 
was maintained also in presence of a leukemic stroma. 
Compared to spontaneous apoptosis of leukemic cells, we 
observed 2.1 ± 0.2 fold change of apoptosis in AML cells 
treated with ATP plus ARA-C in presence of AML-MSCs 
(Figure 3C). The increase was significantly higher than 
Figure 1: ATP triggers apoptosis of leukemia cells from AML patients via P2X7 activation. Leukemic cells isolated from AML 
patients were treated for 48 h with increasing doses of ATP, with or without (w/o) 10 µM AZ 10606120. Data are represented as mean +/− SEM 
(A) CellTiter 96 Aqueous One Solution assay was used to detect viability (n = 14) and (B) Annexin V/PI staining was used to detect apoptosis 
(n = 23). (C–D) To inhibit P2X7 expression, AML cells were nucleofected with a Non Targeting control siRNA or with P2X7-specific siRNA. 
After overnight, cells were treated with 5 mM ATP for 24 h, with or w/o 10 µM AZ 10606120 (n = 4). Results are expressed as fold-change of 
Annexin-V+ cells respect to untreated cells, for each group (% Annexin-V+ cells: 22.4 ± 7% control, 19 ± 6% Non Targeting Control siRNA, 
23.4 ± 9.6% P2X7 siRNA). (C) Representative flow cytometric analysis of P2X7 expression after siRNA treatment. *p < 0.05.
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AML cells treated with ATP or ARA-C alone in presence 
of stroma (1.5 ± 0.2 and 1.1 ± 0.2, respectively, p < 0.05).
Taken together, our results demonstrate that ATP 
antineoplastic activity is maintained also in presence of 
mesenchymal stromal cell. Moreover, the usage of ATP as 
adjuvant could bypasses stroma induced-chemoresistance 
and  potentiates ARA-C cytotoxicity.
ATP has direct toxicity on LSCs 
Several studies [27, 28] indicate a central role of 
LSCs in both the genesis and the perpetuation of AML 
but standard chemotherapy approaches may not effectively 
target the LSC population. To date there are numerous 
studies on P2X7R expression by tumor cells, including 
leukemia cells, but there are no data about its expression 
on LSCs. In order to investigate the efficacy of ATP 
treatment in leukemia stem progenitor compartment, we 
first examined P2X7R expression in four different LSC 
subsets: CD34-CD38-, CD34+CD38-, CD34+CD38+, CD34-
CD38+. Flow cytometric analysis of 22 AML BM samples 
showed that P2X7R is expressed by all populations 
analyzed although higher expression was seen in more 
differentiated progenitor cells (Figure 4A). Next, we 
tested ATP toxicity on LSC compartment. To this end, 
we purified LSC populations from 4 AML BM samples, 
two samples showed > 40% and the other two samples < 
20% of P2X7R+ cells in all subsets. Then, we treated them 
with 5 mM ATP for 48 h. As shown in Figure 4B, ATP 
exposure induced a reduction of viability combined with a 
cytotoxicity index increase in all subpopulations analyzed. 
Specifically, percentage of viability and fold change 
Figure 2: P2X7 activation induces mitochondrial stress and activation of caspase cascade. AML cells were treated with 
5 mM ATP with or w/o 10 µM AZ 10606120 for 48 h. (A) Effect of ATP on transmembrane potential in mitochondria was detected by 
FACS analysis. The bar graphs show the percentage of JC-1 aggregates (cells emitting red fluorescence in the FL-2 channel) and JC-1 
monomers (cells emitting green JC-1 detected in the FL-1 channel) from 6 independent experiments. Data are represented as mean +/− 
SEM (B) Representative dot plots showing JC-1 staining. (C) Immunofluorescence analysis of activated caspase-3 (green), nuclei was 
counterstained with DAPI (blue). 40× magnification, scale bar 20 µm. (D) The histogram summarizes the percentage of activated caspase-3 
from 6 independent experiments at FACS analysis. Data are represented as mean +/− SEM (E) Representative overlay of an independent 
experiment. *p < 0.05, **p < 0.01, n.s., not significant.
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of cytotoxicity index of treated cells were: 60.5 ± 2.5% 
and 1.6 ± 0.2 for CD34-CD38- cells, 68.5 ± 0.5% and 
1.6 ± 0.7 for CD34+CD38- cells, 60.0 ± 10% and 1.5 ± 0.2 
for CD34+CD38+ cells, 61.5 ± 27.5% and 2.1 ± 0.5 for 
CD34−CD38+. Similarly to total AML cells (Figure 1), 
increased cytotoxicity was due to induction of apoptosis 
as demonstrated by increased caspase-3/7 activity. 
Interestingly, also primitive progenitors, which express 
lower level of P2X7R, showed sensitivity to ATP-
mediated cytotoxicity, thus suggesting that ATP may act 
also on cells with reduced P2X7R expression.
Taken together our results demonstrate that ATP 
treatment is effective at inducing toxicity not only in 
leukemic blasts but, more importantly, also in LSCs. 
High dose ATP does not affect normal 
hematopoietic stem cell compartment
Along with the identification of drugs which 
eradicate leukemia at the level of LSCs, minimizing 
the toxicity of antineoplastic agents on the normal 
HSC compartment represents a major task. In order to 
test ATP cytotoxicity on HSC compartment, normal 
CD34+ cells were treated with increasing doses of ATP, 
under the same culture conditions used for AML cells. 
Interestingly, this treatment readily reduced viability and 
induced apoptosis of AML cells, whereas normal CD34+ 
cells were almost entirely unaffected (Figure 5A–5B). 
Analysis of AML sample at the highest ATP concentration 
showed an average viability of 54.8 ± 9.2 % after 48h ATP 
exposure. In contrast, normal CD34+ samples showed 
an average viability of  92.5 ± 0.5 % when analyzed by 
using the same condition (p < 0.05). We also tested the 
ATP treatment on normal HSC subsets. Based on the 
gating strategies used for AML samples and illustrated 
in Figure 5, we separated four progenitor subpopulations 
from 3 normal BM samples and tested their ability to 
respond to ATP treatment. Conversely to LSC subsets, 
normal hematopoietic progenitors showed no variation in 
cell viability after high ATP dosage exposure (Figure 5C).
These results provide evidence that high ATP dosage 
does not impair normal stem cell compartment, which is 
Figure 3: Stroma cells do not affect antineoplastic activity of ATP. (A) AML cells were cultured alone or in presence of normal-
MSCs and AML-MSCs stroma, at the ratio 10:1. After overnight, 5 mM ATP with or w/o 10 µM AZ 10606120 was added to the culture. 
Apoptosis induction was detected after 48 h by FACS analysis of Annexin-V+ cells. Results are expressed as fold change of Annexin-V+ 
cells, untreated AML cells cultured alone (39.6 ± 5.7 %) were used as reference and set as 1 (n = 7). (B) AML cells were treated for 48 h with 
increasing doses of ARA-C with or without 5 mM ATP and analyzed for apoptosis by flow cytometry (n = 6). (C) AML cells were cultured 
alone or in presence of AML-MSCs stroma, at the ratio 10:1. After overnight, 5 mM ATP with or w/o 4 µM ARA-C was added to the culture. 
Apoptosis induction was detected after 48 h. Results are expressed as fold change of Annexin-V+ cells, untreated AML cells cultured alone 
(Annexin-V+ cells: 31.6 ± 5.5%) were used as reference and set as 1. Data are represented as mean +/− SEM in all histograms (n = 6). *p < 0.05.
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Figure 4: ATP exerts a direct toxicity on LSCs. (A) Flow cytometric analysis of P2X7 expression on leukemic stem progenitor 
subsets (n = 22). (B) ApoTox-Glo Triplex assay showing the viability, the cytotoxicity (RFU) and apoptosis (CPS) of highly purified LSC 
subsets treated with 5 mM ATP for 48 h. Results from cytotoxicity and Caspase-3/7 activity assay are expressed as fold-change of RFU and 
CPS, respectively. Untreated cells are used as reference and set as 1. Data are represented as mean +/− SEM (n = 4). *p < 0.05, **p < 0.01.
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an essential aspect for a complete hematologic recovery 
after therapy.
In vivo ATP administration reduces leukemia cell 
growth
To asses if ATP antitumor effect observed in vitro 
also occurs in vivo, we investigated the pharmacologic 
effect of ATP administration in xenotransplanted mice. 
We used two experimental groups (Figure 6A). In the 
first one, we assessed the effect of ATP treatment on 
freshly implanted leukemia by administrating ATP 
starting the day after tumor inoculation. In the second 
one, the change in rate of growth of an established 
leukemia after ATP treatment was assessed. The same 
therapeutic regimen was used, but treatment was 
commenced once human engraftment was greater than 
0.1% in peniferal blood of mice. As shown in Figure 
6B, we observed a reduction of about 40% of human 
leukemia engraftment three months after the end of 
treatment, in both experimental groups (percentage of 
human engraftment: 57.3 ± 13.0% and 65.5 ± 5.4%, 
in first and second group respectively. p < 0.01), in 
agreement with the results from in vitro experiments. 
At necroscopy, control mice had enlarged spleen 
in comparison to ATP treated groups (Figure 6C). 
Treatment was well tolerated as suggested by the 
maintenance of body weight and the lack of toxicity 
primary signs, such as lethargy, ruffled fur, respiratory 
distress and hunchback posture (data not shown). 
Figure 5: HSCs were almost entirely unaffected by ATP treatment. Leukemic cells isolated from AML patients and normal 
CD34+ isolated from healthy donors were treated for 48 h with increasing doses of ATP. (A) CellTiter 96 Aqueous One Solution assay was 
used to detect viability (AML n = 14, donor n = 4) and (B) Annexin V/PI staining was used to detect apoptosis (AML n = 23, donor n = 4). 
(C) CellTiter 96 Aqueous One Solution assay was used to detect viability of HSC and LSC subsets treated with 5 mM ATP for 48 h (AML 
n = 4, donor n = 3). Data are represented as mean +/− SEM in all histograms. *p < 0.05, **p < 0.01 significant with respect to untreated cells.
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These results indicate that in vivo ATP administration 
is well tolerated and efficiently reduce leukemia cell 
growth, therefore they provide solid evidence for the 
further evaluation of ATP in clinical trials.
DISCUSSION
LSCs resistance to current therapies as well as 
treatment-related toxicity are the main cause of failure 
in AML patients especially if elderly. More than 70% 
of AML occur in adults aged > 60 years, who are often 
unable to receive chemotherapy and whose prognosis is, 
consequently, poor [29, 30]. Therefore, the development 
of therapeutic approaches that target LSC population 
minimizing toxicity on HSCs, essential for a complete 
hematological recovery after treatment, is highly 
warranted.
There is growing interest in the therapeutic 
potential of purinergic signaling for the treatment of 
cancer [31]. After the first reports by Rapaport in 1983 
who demonstrated that exogenous ATP inhibited cell 
growth of adenocarcinomatous pancreatic and colon 
cancer cells [32], subsequent papers have shown an anti-
tumoral effect of extracellular nucleotides in various 
cancer cell types [31]. Interestingly, our recent studies 
reported that ATP exerts opposite effects on HSCs 
and AML cells [24]. However, the complete picture is 
probably more complicated and could be dependent upon 
the kind of malignancy analyzed. Purinergic receptors 
like P2X7R have been shown to promote cancer growth 
and progression in certain conditions [21, 33] while, in 
some case, to partially prevent cancer growth by immune 
infiltration [34, 35].
In the present study, we sought to investigate the 
use of ATP for P2X7R pro-apoptotic signaling activation 
specifically on LSCs. We demonstrated that AML cells 
exposed to high ATP dosage show a reduced viability 
and undergo apoptosis, as demonstrated by the increased 
mitochondrial permeability and by activation of caspase 
cascade. In line with previous reports on cell lines [22, 23], 
we confirmed that ATP cytotoxicity is mediated by P2X7R 
activation on primary leukemia cells.
BM microenvironment has an important role 
in several aspects of AML, including development, 
progression and resistance to chemotherapy [36]. To 
better analyze the antineoplastic effect of ATP, we tested 
the treatment by co-culturing AML cells with MSCs, thus 
mimicking BM microenvironment. Several pro-survival 
Figure 6: ATP administration reduces leukemia cell growth in NSG mice. (A) Schematic representation of treatment schedule: 
NSG mice were injected with 1 × 106 i.v. cells. In the first group, the day after human leukemia transplanted, 50 mM ATP was administrated 
every other day for 30 days; in the second group, the same therapeutic regimen started once AML was established. (B) The histogram 
summarizes results from four independent experiments which were  performed using leukemia cells from 4 different AML patients. Results 
represent the percentage of human cell engraftment in mice, 3 months after the end of ATP treatment. Percentage of human engraftment in 
CTR mice (24.9 ± 16.9%) was used as reference and set as 100%. Data are represented as mean +/− SEM. (C) In upper panel, representative 
plots of the percentage of human tumor cells in peripheral blood samples of mice. In lower panel, spleen size of CTR vs ATP treated mice. 
*p < 0.05, **p < 0.01.
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and anti-apoptotic signals in AML cells are activated 
by the stroma [37], including the phosphatidylinositol 
3-kinase (PI3K)/protein kinase B (AKT)/mammalian 
target of rapamycin (mTOR) [38, 39] pathway (PI3K/
AKT/mTOR), which weaken the response of leukemic 
cells to conventional chemotherapy. Since it was described 
that P2X7R activation by ATP leads to a concurrent 
blockade of the mTOR signalling [22], we hypothesized 
that ATP treatment could interfere in stroma-induced 
anti-apoptotic signals in AML cells. Interestingly, we 
observed that both normal and AML-derived stroma did 
not affect the pro-apoptotic ATP effect on leukemia blasts, 
suggesting that potential therapeutic treatment with ATP 
could bypass stroma-mediated AML resistance. Moreover, 
considering that P2X7R pore formation facilitates the 
passage of hydrophilic chemotherapeutic agents [26], we 
hypothesized that the addition of ATP would counteract 
stroma induced-chemoresistance and would potentiate 
the cytotoxic effect of chemotherapeutics. The principle 
of combined therapy is to maximize antineoplastic 
activity while minimizing toxic side effect of treatment. 
This is best attained by combining drugs with different 
mechanisms of action. We demonstrated that ATP 
combined with ARA-C significantly increases its effect 
on cell death and reduces the chemotherapeutic drug 
concentration needed to obtain high level of cytotoxicity 
on leukemia cells, also in presence of a stroma. These 
data may have interesting clinical implications for the 
management of frail elderly AML individuals, generally 
unfit to chemotherapy at standard dosage. Indeed, the use 
of ATP as adjuvant to conventional chemotherapeutics 
may allow to reduce their dosage and toxicity, while 
maintaining their therapautic efficacy.
Despite the accumulating evidence that P2X7R is 
overexpressed by tumor cells, no data are available about 
its expression on LSCs. We report for the first time that 
leukemic stem progenitor subsets express P2X7R and 
interestingly its activation by high ATP dose effectively 
affects LSCs viability, inducing apoptosis. In contrast, 
HSCs appear to be resistant to the same treatment. These 
findings clearly demonstrate that activation of the same 
receptor by ATP on normal and leukemic cells could 
selectively target LSCs and it represents a good premise for 
the development of new therapeutic strategies. Although 
the underlying mechanism of this opposite effect is not yet 
clarified, our hypothesis is that a differential expression of 
P2X7R isoform on normal and leukemic cells may occur. 
Nine different human splice variants of P2X7R receptor 
have been identified (P2X7RA-J), four of these lack the 
extended C-terminal tail typical of the full-length receptor 
(P2X7RA) [40,41]. Among the truncated splice variants, 
P2X7RB exerts a trophic activity in HEK293 cells, losing 
the pro apoptotic function of P2X7RA. Interestingly, 
P2X7RB acts as dominant positive subunit by enhancing 
all its known functions, including apoptotic pore opening 
and cell growth, when co-expressed with P2X7RA 
[42]. Moreover, P2X7RA and P2X7RB isoforms have 
differential effects on cell growth and on mineralization of 
osteosarcoma cells [43]. We demonstrated that in normal 
HSCs P2X7RB is the predominant isoform (manuscript 
in preparation) and even if high ATP concentrations will 
occur, they fail to cause pore formation. The preferential 
expression of P2X7RB in normal CD34+ could be one 
of the mechanism by which HSCs sense the high ATP 
concentration in site of inflammation as growth stimulus, 
protecting themselves from apoptosis.
In keeping with in vitro experiments, we 
demonstrated that ATP antineoplastic effect also occurs 
in vivo. ATP administration significantly reduced human 
leukemia growth in NSG mice, without causing any 
adverse side effects in treated animals. The present results 
are the first evidence of the efficacy of ATP treatment in 
haematological malignancies in vivo and they are in line 
with those described in murine models of solid tumors, 
such as colon and pancreatic cancer [44], melanoma 
[45], bladder [46] and prostate [47] cancer. In our in vivo 
experiments, high ATP concentration has been used to 
level that exceeds the dose permitted in humans. However, 
since murine blood has higher ecto-ATPase activity 
in vitro compared to human blood [46] thus leading to 
a greater breakdown of ATP, we would expect to obtain 
the same therapeutic effect in patients by using a lower 
concentration.
Several clinical application of extracellular ATP 
have been reported in several fields, including oncology 
[48–52]. Studies from Agteresch [49, 50, 52] demonstrated 
the safety of ATP infusion in patient with lung cancer. 
ATP treatment was well tolerated and if side effects 
occur, they were mild and transient. In randomised 
trials, overall survival time of patients with advanced 
stage IIIB non-small cell lung cancer increased from 9.3 
months in the ATP-treated vs 3.5 months for the control 
group. Furthermore, Beijer and colleagues showed that, 
in contrast to many conventional antitumor regimens, 
ATP infusions may have a beneficial effect on survival 
without negatively affecting quality of life of cancer 
patients affected by various solid tumors [48, 51]. It has 
also been demonstrated that ATP administration reduced 
disease activity and inflammation in a patient with active 
rheumatoid arthritis [53].
In conclusion, P2X7R stimulation by ATP induced 
a therapeutic response in blasts from AML patients and 
more importantly in LSCs, while did not affect HSC 
compartment. Moreover ATP potentiated the cytotoxic 
effect of chemotherapic drugs, allowing to reduce their 
dose. Murine model confirmed the antileukemic activity 
in vivo.
These results provide evidence that ATP would be 




Cell isolation and culture
Primary leukemic cells were obtained from 
peripheral or bone marrow blood of 34 AML patients 
at diagnosis, before treatment (Supplementary Data, 
Supplementary Table S1). The percentage of leukemic 
blasts was always > 90%. Normal mononuclear cells 
(MNCs) were obtained from BM healthy donors. 
Mononuclear cells were isolated by Ficoll-Hypaque 
centrifugation (Amersham Bioscience, Piscataway, NJ, 
USA). In some experiments, normal PB MNCs were 
processed by MiniMacs high-gradient magnetic separation 
column (Miltenyi Biotec, Bergisch Gladbach, Germany) to 
obtain highly purified CD34+ cells.
For in vitro studies, cells were cultured in RPMI 
1640 medium supplemented with 10% FBS (GIBCO, 
Thermo Fisher Scientific, MA, USA) in presence of 
increasing dose of ATP (Sigma Aldrich, Germany) and 
ARA-C (Sigma Aldrich). In some experiments, cells were 
pre-treated for 30 min at 37°C with 10 µM AZ 10606120, 
a P2X7R specific antagonist (Tocris, Bristol, United 
Kingdom).
The pH of ATP solution was adjusted to 6.8 using 
NaOH for both in vitro and in vivo experiments.
The research was approved by the Ethics Committee 
of Policlinico S.Orsola-Malpighi, University Hospital of 
Bologna and each individual gave written informed consent 
(Ethical Committee approval code: 147/2013/O/Tess).
Viability assay
CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega Corporation, Madison, 
WI, USA) was used to detect cell viability. Five × 105 
cells/100 µl culture medium were seeded into 96-well 
microplate and treated as indicated. After culture, CellTiter 
96 AQueous One Solution reagent was added to each well 
and the microplate was incubated for 4 h at 37°C in 5% 
humidified CO2. Optical density value was measured by 
an ELISA plate reader (Multiskan Ex, Thermo Electron 
Corporation, San Josè, CA, USA) at a wavelength of 492 
nm. Each variant group was performed in triplicate wells.
Apoptosis 
Apoptosis was measured with Annexin-V-FLUOS 
Staining Kit (Roche, Mannheim, Germany) followed by 
flow cytometric analysis (BD AccuriTM C6, BD Becton 
Dickinson, NJ USA. FCS Express 4 Software, De Novo 
Software, Los Angeles, CA USA). After the indicated 
treatment, cells were harvested and stained according to 
manufacturer’s instructions. Briefly, 1 × 106 cells were 
resuspended in 100 µl Incubation Buffer, stained with 2 µl 
FITC-conjugated Annexin-V and 2 µl propidium iodide 
(PI) for 10 min at room temperature and analyzed. Results 
were compared to the apoptotic rate of untreated cells. 
siRNA transfection of AML cells
AML cells were transfected with 350 nM SMARTpool 
ON-TARGETplus P2RX7 siRNA (Dharmacon, Lafayette, 
CO), using standard Nucleofector Amaxa Thecnology 
(Amaxa Biosystem, Germany) [54]. Briefly, 2 × 106 AML 
cells were transfected by using the U08 program. The target 
sequences were: i) GCGGUUGUGUCCCGAGUAU, ii) 
GGAUCCAGAGCAUGAAUUA, iii) GCUUUGCUCUG 
GUGAGUGA, iiii) GGAUAGCAGAGGUGAAAGA. 
ON-TARGETplus Non-targeting Control Pool designed 
and tested for minimal targeting of human genes was used 
as negative control (Dharmacon). After 24 h incubation, 
AML cells were treated with 5 mM ATP with or without 
10 µM AZ 10606120 for 24 h.
Active caspase-3 expression
Flow cytometric analysis of active caspase-3 was 
performed using Fixation Permeabilization kit (BD) 
for intracellular staining and human active Caspase-3-
PE monoclonal antibody (BD), according to protocol’s 
instruction. BD AccuriTM C6 cytometer and FCS Express 
4 Software were used.
For immunofluorescence staining, cells were fixed 
in 4% parafolmaldehyde and permeabilized with 0.25% 
Triton. The staining was performed using anti-Human 
CASP3 monoclonal antibody (Invitrogen, CA USA) and 
anti-Rabbit FITC secondary antibody (Dako, Denmark). 
Cell were examined under fluorescence Axiovert 
microscope with a CCD camera (Zeiss, Germany)
Mitochondrial membrane potential 
measurement
The variation in ΔΨm was investigated using the 
BD™ MitoScreen Kit (BD) according to the manufacturer’s 
instruction. Briefly, 1 × 106 cells were harvested from the 
suspension cultures, washed twice with PBS and incubated 
with JC-1 solution for 15 min at 37°C. JC-1 monomers 
or aggregates were analyzed by flow cytometry (BD 
AccuriTM C6 cytometer and FCS Express 4 Software).
Co-culture of AML cells with MSCs
Normal or AML MSCs, isolated as previously 
described [55], were seeded in 96 well plates 1 × 104/
well, AML cells were added to the confluent layer at 10:1 
ratio. After overnight incubation, cells were treated as 
indicated. After 48 h treatment, AML cells were harvested 
for analysis, leaving MSC stroma intact.
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Flow cytometry and cell sorting
P2X7R expression in LSC subsets was analyzed by 
flow cytometry (BD AccuriTM C6 cytometer and FCS 
Express 4 Software). BM cells from 22 AML samples 
were labelled with an anti-P2X7R FITC (Alomone Labs, 
Israel), anti-CD34 APC (BD) and Anti-CD38 PE (BD) 
monoclonal antibodies.
Leukemic and normal stem/progenitor cell subset 
were purified by cell sorting strategy. BM MNCs 
were stained with human CD34-FITC and CD38-APC 
monoclonal antibodies (BD) and sorted on FACSAria 
(BD). Aliquots of sorted populations were reanalyzed 
to assess their purities, which were always found to be 
greater than 98%.
Caspase-3/7 activity assay
ApoTox-Glo™ Triplex Assay (Promega) was 
used to assess cytotoxicity and caspase-3/7 activity in 
LSC subsets. Cells were plated in 96-well plate (2,000 
cells/100 µl /well) and treated with 5 mM ATP for 48 h. 
At the end of culture, according to protocol’s instruction, 
we added 20 μl of Viability/Cytotoxicity Reagent to 
each well. After 30 min incubation at 37°C, cell viability 
and cytotoxicity (wavelength 400Ex/505Em, 485Ex/520Em 
respectively) were assessed by measuring fluorescence 
with Victor2 Microplate Reader (Perkin Elmer, MA USA). 
After the measurement of cell viability, the caspase-Glo 
3/7 reagent was added into each well, the plates were 
briefly mixed by an orbital shaker and incubated for 
30 min at 37°C. Caspase-3 activation was determined by 
measuring luminescence with Victor2 Microplate Reader. 
Each variant group was performed in triplicate wells.
Xenotransplant experiments
Experiments were carried out on nonobese 
diabetic severe combined immunodeficient (NOD/SCID) 
interleukin-2 receptor g (IL-2Rg)–null (NSG) mice, 6 
to 8-weeks-old. NSG mice were bred and housed under 
pathogen-free conditions in the animal facilities at the 
European Institute of Oncology–Italian Foundation for 
Cancer Research (FIRC) Institute of Molecular Oncology 
(IEO-IFOM, Milan, Italy). All animal experiments were 
done in accordance with the Italian Laws (D.L.vo 26/2014 
and following additions), and institutional guidelines, 
and were approved by the Italian Ministry of Health. For 
induction of human leukemia, 1 × 106 AML cells were 
injected intravenously through the lateral tail vein of 
sublethally irradiated mice. Primary cells from 4 different 
AML patients were used.
Two experimental treatment design were used. In 
the first group, one day after cell transfer 50 mM ATP 
in 0.25 ml sterile saline was administered for 30 days, 
every other day by i.p. injection. In the second group, 
the same therapeutic regime was used as before, but the 
treatment started once AML was established. A control 
group (CTR) received i.p. an equivalent volume of the 
vehicle (sterile saline solution). Five mice were randomly 
picked and assigned to each experimental group. Human 
cell engraftment in the peripheral blood from tail vein was 
investigated by flow cytometry. Cells were stained with 
anti-human CD45-APC (Beckman-Coulter, CA, USA) and 
anti-mouse CD45-PE (BD) antibodies. After red cell lysis, 
cell suspensions were evaluated by a FACSCalibur (BD). 
Seven-aminoactinomycin D (7AAD; Sigma-Aldrich) was 
used to enumerate viable, apoptotic and dead cells.
Statistical analysis
Results are expressed as means ± SEM
Depending on experimental conditions, statistical 
analysis will be performed using t test or ANOVA 
followed by a post hoc test (Bonferroni or Dunnet’s) 
(GraphPad Prism, version 6.03). P < 0.05 was considered 
statistically significant.
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